JAMA Netw Open
Experts outline when to deprescribe psychotropic medications
The American Society of Clinical Psychopharmacology convened a panel of 45 international experts who completed a multiround Delphi survey and focused literature review to identify areas of agreement and disagreement on deprescribing psychotropic medications. The panel reached consensus on 44 of 50 statements (88%), endorsing routine regimen review and shared, risk‑benefit decision‑making. Notably, the panel didn’t reach consensus on deprescribing valproate in women of childbearing potential despite substantial evidence of teratogenic risk; dissenting panelists emphasized individualized clinical context. The group also supported deprescribing non–evidence‑based polypharmacy and highlighted the importance of recognizing drug‑drug interactions, using cross‑tapering strategies, and maintaining patient‑centered dialogue.
Key points of consensus
- Confirm adherence before deprescribing.
- Consider deprescribing with minimal response or once goals are met without long‑term relapse concerns.
- Evaluate psychological implications.
- Provide close monitoring.
- Use shared decision‑making.
Clinical takeaway: Make deprescribing a deliberate, collaborative process, especially when balancing nuanced risks, alternatives, and treatment endpoints.
Source:
Goldberg JF, et al; American Society of Clinical Psychopharmacology Task Force on the Deprescribing of Psychotropic Medications. (2026, February 25). JAMA Netw Open. Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force. https://pubmed.ncbi.nlm.nih.gov/41739481/